Developer docs
API playgroundTry for free, no card

Search company profiles

Divide and Conquer

Full company profile

uuid0003opa

Namestring
Divide and Conquer
Websiteurl
conquer.bio
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Divide and Conquer is a private, early-stage biotechnology company headquartered in Cambridge, United States, founded in 2018. The company is focused on the discovery and development of a new class of oncology therapeutics. With a stated headcount of 1-10 employees, the firm operates at a small scale consistent with preclinical or discovery-stage biotech operations, and its public web presence (conquer.bio) currently shows only a default cPanel parked page, indicating minimal commercial-facing footprint.

The company has attracted institutional capital from Medicxi, a healthcare-dedicated investment firm, securing a $12,433,002 financing round dated September 23, 2019. This funding round, classified in the available records as the company's Round 2, represents the principal disclosed capital event and indicates progression through early biotech financing stages. David Grainger is identified in available records as a Director, providing governance oversight.

The underlying therapeutic platform, specific molecular targets, pipeline composition, business model mechanics, pricing structure, partnerships relevant to the oncology thesis, and customer or commercialization profile are not disclosed in the available source material. This degree of information scarcity is typical of stealth-mode or pre-clinical biotech entities, and it materially limits the visibility of near-term milestones and revenue trajectories. Note that some source records associate the company name "Divide and Conquer" / "Divide/Conquer" with a film-production entity (e.g., partnerships with Legendary Entertainment and Angry Films Entertainment on the Faces of Death remake); the relevance of those data to the biotech thesis is unclear from the source material and is flagged for diligence.

Short descriptiontext

Divide and Conquer is a Cambridge, US-based private biotechnology company founded in 2018 that is developing a new class of oncology therapeutics. It is backed by healthcare-focused investor Medicxi and operates with a small early-stage team.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
oncology therapeutics, biotechnology research, drug discovery, cancer treatment development, biopharmaceutical development
Industry1 code
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Therapeutics
Social media profiles1 record
Cost components4 values
Personnel, Technology or R&D, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Divide and Conquer (also styled as Divide/Conquer) is a biotechnology company founded in 2018 and headquartered in Cambridge, Massachusetts. The company operates with a small team of 1-10 employees focused on the discovery and development of a new class of oncology therapeutics. Its work centers on early-stage cancer drug discovery and biological research to address unmet needs in oncology treatment.

Differentiator
Functional benefit
Problem solved
Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Legendary Entertainment is a co-producer on the Faces of Death remake. The production involves Legendary Entertainment, Angry Films Entertainment, and Divide/Conquer, with the project having been in development for 16 years before reaching production. The film is set for release on April 10.

2Angry Films Entertainment
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Angry Films Entertainment is a co-producer on the Faces of Death remake alongside Legendary Entertainment and Divide/Conquer. The project has been in development for 16 years.

variety.com
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Cambridge, UK-based clinical-stage biotech developing bicyclic peptides for oncology. Directly comparable geography, stage, and therapeutic focus, and a typical reference point for differentiated-mechanism oncology biotechs emerging from the Cambridge cluster.

TypeDirect peer
Description

Cambridge, UK-based developer of T-cell engagers and immune-oncology biologics. Comparable in size, stage, and oncology focus, and another example of a Cambridge-anchored biotech pursuing a defined class of cancer therapeutics.

TypeDirect peer
Description

UK-based oncology biotech (also previously backed by Medicxi) developing small-molecule cancer therapeutics. Highly comparable given shared VC backing and oncology focus, and illustrates the typical trajectory and challenges for Medicxi oncology assets.

TypeDirect peer
Description

London-based clinical-stage biotech developing personalised neoantigen cancer immunotherapies. Similar UK-base, oncology focus, and emerging-stage profile, providing a useful stage-comparable for forward planning.

TypeDirect peer
Description

Cambridge-area biotech developing tetravalent bispecific antibodies for oncology and immunology. Comparable geography, modality innovation angle, and oncology focus, and illustrates the path from discovery biotech to clinical/partnered asset.

TypeBroad incumbent
Description

Oxfordshire-headquartered clinical-stage biotech developing engineered TCR therapies for solid tumours. Same UK oncology orientation but at meaningfully larger scale and public-company status, serving as a broader-incumbent reference point.

TypeBroad incumbent
Description

London-headquartered clinical-stage biotech developing programmed CAR-T cell therapies for cancer. Same UK oncology innovation ecosystem, listed on Nasdaq, and provides a useful scale reference for what a successful UK oncology biotech trajectory looks like.

TypeEmerging player
Description

Oxford-based immunology and oncology biotech, also backed by Medicxi. Shares the Medicxi oncology/immunology platform and UK-base with Divide and Conquer, making it a relevant emerging-player peer for understanding capital and pipeline expectations.

TypeBroad incumbent
Description

Global biopharma headquartered in Cambridge, UK with one of the world's largest oncology pipelines. Functions as a broad-incumbent reference point and a likely potential acquirer or partner for any Cambridge oncology biotech with a differentiated mechanism.

TypeRegional player
Description

Belgium-based clinical-stage biotech developing mRNA-based immunotherapies for cancer. Operates in a closely related modality space (cancer immunotherapy) but is regional (continental Europe) rather than directly UK-based, making it a useful regional peer.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Divide and Conquer

Oncology Therapeuticsconquer.bio

Divide and Conquer is a Cambridge, US-based private biotechnology company founded in 2018 that is developing a new class of oncology therapeutics. It is backed by healthcare-focused investor Medicxi and operates with a small early-stage team.

What Divide and Conquer does

Divide and Conquer is a private, early-stage biotechnology company headquartered in Cambridge, United States, founded in 2018. The company is focused on the discovery and development of a new class of oncology therapeutics. With a stated headcount of 1-10 employees, the firm operates at a small scale consistent with preclinical or discovery-stage biotech operations, and its public web presence (conquer.bio) currently shows only a default cPanel parked page, indicating minimal commercial-facing footprint.

The company has attracted institutional capital from Medicxi, a healthcare-dedicated investment firm, securing a $12,433,002 financing round dated September 23, 2019. This funding round, classified in the available records as the company's Round 2, represents the principal disclosed capital event and indicates progression through early biotech financing stages. David Grainger is identified in available records as a Director, providing governance oversight.

The underlying therapeutic platform, specific molecular targets, pipeline composition, business model mechanics, pricing structure, partnerships relevant to the oncology thesis, and customer or commercialization profile are not disclosed in the available source material. This degree of information scarcity is typical of stealth-mode or pre-clinical biotech entities, and it materially limits the visibility of near-term milestones and revenue trajectories. Note that some source records associate the company name "Divide and Conquer" / "Divide/Conquer" with a film-production entity (e.g., partnerships with Legendary Entertainment and Angry Films Entertainment on the Faces of Death remake); the relevance of those data to the biotech thesis is unclear from the source material and is flagged for diligence.

Divide and Conquer firmographics

Firmographics
Name
Divide and Conquer
Website
https://conquer.bio
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
Divide and Conquer is a Cambridge, US-based private biotechnology company founded in 2018 that is developing a new class of oncology therapeutics. It is backed by healthcare-focused investor Medicxi and operates with a small early-stage team.
Ownership category
akta.pro rank

Divide and Conquer industry classification

Industry
Product category
Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Oncology therapeutics
  • Biotechnology research
  • Drug discovery
  • Cancer treatment development
  • Biopharmaceutical development

Where Divide and Conquer is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Markets served

Divide and Conquer business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure

Divide and Conquer product offering

Product offering

Core offering

Divide and Conquer (also styled as Divide/Conquer) is a biotechnology company founded in 2018 and headquartered in Cambridge, Massachusetts. The company operates with a small team of 1-10 employees focused on the discovery and development of a new class of oncology therapeutics. Its work centers on early-stage cancer drug discovery and biological research to address unmet needs in oncology treatment.

Differentiator

Problem solved

Functional benefit

Companies that use Divide and Conquer

Customer profile

Ideal customer profiles1 record

Divide and Conquer technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Divide and Conquer partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Legendary EntertainmentcoreStrategic or Co-development PartnerLegendary Entertainment is a co-producer on the Faces of Death remake. The production involves Legendary Entertainment, Angry Films Entertainment, and Divide/Conquer, with the project having been in development for 16 years before reaching production. The film is set for release on April 10.
  • Angry Films EntertainmentcoreStrategic or Co-development PartnerAngry Films Entertainment is a co-producer on the Faces of Death remake alongside Legendary Entertainment and Divide/Conquer. The project has been in development for 16 years.

Recent moves3 records

Expansion highlights3 records

Divide and Conquer competitors and assessment

Company assessment

Direct peers

  • Bicycle Therapeutics: Cambridge, UK-based clinical-stage biotech developing bicyclic peptides for oncology. Directly comparable geography, stage, and therapeutic focus, and a typical reference point for differentiated-mechanism oncology biotechs emerging from the Cambridge cluster.
  • Crescendo Biologics: Cambridge, UK-based developer of T-cell engagers and immune-oncology biologics. Comparable in size, stage, and oncology focus, and another example of a Cambridge-anchored biotech pursuing a defined class of cancer therapeutics.
  • CellCentric: UK-based oncology biotech (also previously backed by Medicxi) developing small-molecule cancer therapeutics. Highly comparable given shared VC backing and oncology focus, and illustrates the typical trajectory and challenges for Medicxi oncology assets.
  • Achilles Therapeutics: London-based clinical-stage biotech developing personalised neoantigen cancer immunotherapies. Similar UK-base, oncology focus, and emerging-stage profile, providing a useful stage-comparable for forward planning.
  • F-star Therapeutics: Cambridge-area biotech developing tetravalent bispecific antibodies for oncology and immunology. Comparable geography, modality innovation angle, and oncology focus, and illustrates the path from discovery biotech to clinical/partnered asset.

Broad incumbents

  • Adaptimmune: Oxfordshire-headquartered clinical-stage biotech developing engineered TCR therapies for solid tumours. Same UK oncology orientation but at meaningfully larger scale and public-company status, serving as a broader-incumbent reference point.
  • Autolus Therapeutics: London-headquartered clinical-stage biotech developing programmed CAR-T cell therapies for cancer. Same UK oncology innovation ecosystem, listed on Nasdaq, and provides a useful scale reference for what a successful UK oncology biotech trajectory looks like.
  • AstraZeneca: Global biopharma headquartered in Cambridge, UK with one of the world's largest oncology pipelines. Functions as a broad-incumbent reference point and a likely potential acquirer or partner for any Cambridge oncology biotech with a differentiated mechanism.

Emerging players

  • Vaccitech: Oxford-based immunology and oncology biotech, also backed by Medicxi. Shares the Medicxi oncology/immunology platform and UK-base with Divide and Conquer, making it a relevant emerging-player peer for understanding capital and pipeline expectations.

Regional players

  • eTheRNA immunotherapies: Belgium-based clinical-stage biotech developing mRNA-based immunotherapies for cancer. Operates in a closely related modality space (cancer immunotherapy) but is regional (continental Europe) rather than directly UK-based, making it a useful regional peer.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

Divide and Conquer social profiles

Digital presence

Divide and Conquer financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Divide and Conquer leadership team

Management profile

Number of profiles

Profiles1 record

Divide and Conquer funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Divide and Conquer M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Divide and Conquer

What does Divide and Conquer do?

Divide and Conquer (also styled as Divide/Conquer) is a biotechnology company founded in 2018 and headquartered in Cambridge, Massachusetts. The company operates with a small team of 1-10 employees focused on the discovery and development of a new class of oncology therapeutics. Its work centers on early-stage cancer drug discovery and biological research to address unmet needs in oncology treatment.

Is Divide and Conquer a public or private company?

Divide and Conquer is a private company. It is classified as venture growth investor backed and is currently operating.

When was Divide and Conquer founded?

Divide and Conquer was founded in 2018. It employs 1 to 10 people.

Where is Divide and Conquer based?

Divide and Conquer is headquartered in Cambridge, United States, in the North America region.

Who are Divide and Conquer's main competitors?

Direct peers on record are Bicycle Therapeutics, Crescendo Biologics, CellCentric, Achilles Therapeutics and F-star Therapeutics. Broad incumbents are Adaptimmune, Autolus Therapeutics and AstraZeneca. Vaccitech is listed as an emerging player. eTheRNA immunotherapies is listed as a regional player.

Does Divide and Conquer have an API?

No public API is recorded for Divide and Conquer.

What industry is Divide and Conquer in?

Divide and Conquer's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals